Cancer Cytopathology最新文献

筛选
英文 中文
Writing our way through academia: Our journey as young faculty and book authors 书写我们的学术之路我们作为青年教师和图书作者的心路历程
IF 3.2 3区 医学
Cancer Cytopathology Pub Date : 2024-09-19 DOI: 10.1002/cncy.22902
Terrance James Lynn MD, Swikrity U. Baskota MD
{"title":"Writing our way through academia: Our journey as young faculty and book authors","authors":"Terrance James Lynn MD, Swikrity U. Baskota MD","doi":"10.1002/cncy.22902","DOIUrl":"10.1002/cncy.22902","url":null,"abstract":"","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"133 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22902","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trichorhinophalangeal syndrome 1 expression in breast and nonbreast metastases from Müllerian, lung, gastrointestinal tract, and pancreatic primary tumors by immunohistochemistry with cytology cell block specimens 通过细胞学细胞块标本的免疫组织化学方法,观察毛细血管畸形综合征 1 在缪勒氏、肺、胃肠道和胰腺原发肿瘤的乳腺和非乳腺转移瘤中的表达情况
IF 3.2 3区 医学
Cancer Cytopathology Pub Date : 2024-09-12 DOI: 10.1002/cncy.22901
Deepak Donthi MD, MPH, Qiong Gan MD, PhD, Qing Qing Ding MD, PhD, Savitri Krishnamurthy MD
{"title":"Trichorhinophalangeal syndrome 1 expression in breast and nonbreast metastases from Müllerian, lung, gastrointestinal tract, and pancreatic primary tumors by immunohistochemistry with cytology cell block specimens","authors":"Deepak Donthi MD, MPH,&nbsp;Qiong Gan MD, PhD,&nbsp;Qing Qing Ding MD, PhD,&nbsp;Savitri Krishnamurthy MD","doi":"10.1002/cncy.22901","DOIUrl":"10.1002/cncy.22901","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Trichorhinophalangeal syndrome 1 (TRPS1) expression in primary breast and other solid tumors has been investigated but its role as a marker in metastatic tumors is unclear. The objective of this study was to evaluate the sensitivity and specificity of TRPS1 as a breast cancer immunomarker in metastatic tumors that originated from breast, Müllerian, lung, gastrointestinal (GI), and pancreatic primary tumors with cell blocks from fine-needle aspiration (FNA) and effusion specimens.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Cell blocks were immunostained with anti-TRPS1 monoclonal antibody (clone EPR16171). Histochemical scores (H scores) (proportion × intensity; range, 0–300) were assigned; H scores of ≥10 were considered positive. Overall, 160 specimens were examined, including 127 FNAs (35 breast, 25 Müllerian, 36 lung, and 31 GI and pancreatic carcinomas) and 33 effusion specimens (18 breast, 12 Müllerian, one lung, and two GI carcinomas).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>TRPS1 was positive in 51 of 53 (96%) metastatic breast carcinomas and in 28 of 107 (26.2%) nonbreast metastatic tumors. Metastatic breast carcinoma showed the highest mean H score of 247.35, compared to 45.36 in Müllerian, 8.4 in lung, and 5.88 in GI tumors. The sensitivity and specificity of TRPS1 for identifying a breast origin in metastatic tumors was 96.22% and 72.89%, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Despite high overall sensitivity, TRPS1 showed lower specificity as a breast immunomarker because of its expression in nonbreast tumors. The mean H score in nonbreast tumors was significantly lower than in metastatic breast tumors. It is important to recognize the broad range of expression of TRPS1 in metastatic breast and nonbreast tumors to avoid an incorrect determination of a metastatic tumor’s organ of origin.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 12","pages":"799-808"},"PeriodicalIF":3.2,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142227082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parsing the thyroid cytopathology suspicious for malignancy diagnosis through molecular-derived risk of malignancy and other related parameters: Insights into nodule characteristics and practice patterns 通过分子衍生的恶性肿瘤风险和其他相关参数解析甲状腺细胞病理学中的恶性肿瘤诊断可疑病例:洞察结节特征和实践模式
IF 3.2 3区 医学
Cancer Cytopathology Pub Date : 2024-09-11 DOI: 10.1002/cncy.22904
David Starr MD, Youley Tjendra MD, Jaylou M. Velez Torres MD, Carmen Gomez-Fernandez MD, Samer N. Khader MD, Esra Karslioglu-French MD, Linwah Yip MD, Sally E. Carty MD, John M. Skaugen MD, Yuri E. Nikiforov MD, PhD, Raja R. Seethala MD, N. Paul Ohori MD
{"title":"Parsing the thyroid cytopathology suspicious for malignancy diagnosis through molecular-derived risk of malignancy and other related parameters: Insights into nodule characteristics and practice patterns","authors":"David Starr MD,&nbsp;Youley Tjendra MD,&nbsp;Jaylou M. Velez Torres MD,&nbsp;Carmen Gomez-Fernandez MD,&nbsp;Samer N. Khader MD,&nbsp;Esra Karslioglu-French MD,&nbsp;Linwah Yip MD,&nbsp;Sally E. Carty MD,&nbsp;John M. Skaugen MD,&nbsp;Yuri E. Nikiforov MD, PhD,&nbsp;Raja R. Seethala MD,&nbsp;N. Paul Ohori MD","doi":"10.1002/cncy.22904","DOIUrl":"10.1002/cncy.22904","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Thyroid cytopathology cases with suspicious for malignancy (SFM) diagnosis often result in resection. However, molecular testing offers details that may provide additional insights. In this study, the molecular profiles of SFM cases from two institutions that routinely used ThyroSeq v3 (TSV3) were examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Following institutional review board approval, SFM thyroid cytopathology cases with TSV3 results were retrieved from the databases of two institutions. Molecular information including molecular-derived risk of malignancy (MDROM), cytologic-histologic correlation data, and other related parameters were calculated. Statistical comparisons were made with a <i>p</i> &lt;.05 considered significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The core data set comprised 114 SFM cases that passed TSV3 quality assurance. All TSV3 results were reported as positive or negative for genomic alterations and all except five cases provided a probability of malignancy estimate. The overall combined baseline MDROM of 75.7% (95% CI, 70.0–81.4) was comparable to the risk of malignancy (74%) published in the Bethesda System. There was a statistically significant difference between the combined MDROMs of resected and unresected cohorts (79.0% vs 58.6%; <i>p</i> = .0153). Interestingly, the MDROMs of the resected cohorts from the two institutions were statistically different (75.0% vs 85.3%; <i>p</i> = .020). Cytologic–histologic correlation revealed malignant outcome in 88.5% of resected cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Molecular analyses of SFM cases demonstrated higher risk genomic alterations that were associated with histologically overt neoplasms, resulting in increased malignancy outcome compared to baseline. MDROM analysis revealed differences in the cytopathologic practice patterns regarding follicular-patterned neoplasms at the two institutions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"133 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142218002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increasing trainee engagement and laboratory feedback during an internal laboratory inspection 在实验室内部检查期间提高受训人员的参与度和实验室反馈意见
IF 3.2 3区 医学
Cancer Cytopathology Pub Date : 2024-09-11 DOI: 10.1002/cncy.22906
Marlo Dilks MHA, Allison Goldberg MD
{"title":"Increasing trainee engagement and laboratory feedback during an internal laboratory inspection","authors":"Marlo Dilks MHA,&nbsp;Allison Goldberg MD","doi":"10.1002/cncy.22906","DOIUrl":"10.1002/cncy.22906","url":null,"abstract":"&lt;p&gt;The inadequacy of laboratory management training has long been reported in the literature,&lt;span&gt;&lt;sup&gt;1-4&lt;/sup&gt;&lt;/span&gt; with various suggestions on ways to improve this aspect of pathology education and better prepare our trainees for the work of a staff pathologist.&lt;span&gt;&lt;sup&gt;5-8&lt;/sup&gt;&lt;/span&gt; The ACGME (Accreditation Council for Graduate Medical Education) milestones directly reflect this educational need and include a requirement of participation in an internal or external laboratory inspection to reach level four, the goal level for graduation, in the residency milestone &lt;i&gt;Systems-based practice 5: Accreditation, compliance, and quality (AP/CP)&lt;/i&gt;. There are similar requirements for many of the pathology fellowships, including &lt;i&gt;Systems-based practice 4: Accreditation, compliance, and quality&lt;/i&gt; for blood banking/transfusion medicine, chemical pathology, cytopathology, dermatopathology, forensic pathology, hematopathology, medical microbiology, neuropathology, and pediatric pathology and &lt;i&gt;Systems-based practice 5: Accreditation, compliance, and quality&lt;/i&gt; in molecular genetic pathology&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; (for a description of milestones by level, seeTable 1). Furthermore, such participation has long been part of &lt;i&gt;laboratory management&lt;/i&gt; curricula.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The literature provides a few specific examples of departmental efforts toward using an internal inspection to support trainee advancement to level four of the &lt;i&gt;accreditation, compliance, and quality&lt;/i&gt; milestone. In one report from the University of Florida, the trainees made up the entire inspection team, with the associate program director serving as the team leader. Four lunchtime seminars covering a range of laboratory management topics were provided, and preinspection and postinspection assessments were performed, showing a significant improvement in trainees' knowledge after the inspection.&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt; Another report from the University of California Irvine Medical Center describes a resident-led self-inspection of the department's histology laboratory and the subsequent decrease in deficiencies and improvement in staff satisfaction survey results for that laboratory.&lt;span&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/span&gt; Finally, a group out of Emory University created a clinical laboratory management curriculum that included preparation for and performance of an out-of-cycle mock inspection in one of the areas of the laboratory.&lt;span&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/span&gt; Those authors report that the curriculum was well received and provided objective measurements of mastery for a range of laboratory medicine concepts. Some subspecialties within pathology have created subspecialty-specific laboratory management education options as well.&lt;span&gt;&lt;sup&gt;13&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;At our institution, we have long included residents and fellows in external inspections when possible and based on specific laboratory management interests and in our internal laboratory inspection in at le","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"133 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22906","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142227083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytologic diagnosis of papillary renal neoplasm with reverse polarity 具有反向极性的乳头状肾肿瘤的细胞学诊断
IF 3.2 3区 医学
Cancer Cytopathology Pub Date : 2024-09-11 DOI: 10.1002/cncy.22903
Sarah J. Wu MD, PhD, Andrew A. Renshaw MD, Peter M. Sadow MD, PhD, Navin R. Mahadevan MD, PhD, Michelle S. Hirsch MD, PhD, Murugesan Manoharan MD, Edmund S. Cibas MD
{"title":"Cytologic diagnosis of papillary renal neoplasm with reverse polarity","authors":"Sarah J. Wu MD, PhD,&nbsp;Andrew A. Renshaw MD,&nbsp;Peter M. Sadow MD, PhD,&nbsp;Navin R. Mahadevan MD, PhD,&nbsp;Michelle S. Hirsch MD, PhD,&nbsp;Murugesan Manoharan MD,&nbsp;Edmund S. Cibas MD","doi":"10.1002/cncy.22903","DOIUrl":"10.1002/cncy.22903","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Papillary renal neoplasm with reverse polarity is a recently recognized low-grade neoplasm with a favorable prognosis. To date, its cytologic features have not been well documented.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Two patients with papillary renal neoplasm with reverse polarity sampled by fine needle aspiration and core needle biopsy are described, one of whom is under active surveillance without clinical progression and the other is alive and well 16 years after partial nephrectomy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The cytologic features included a mix of papillae and dispersed cells with abundant oncocytic cytoplasm and round, bland nuclei apically displaced away from the papillary core. Immunohistochemistry showed positive staining for GATA3 in both cases. Molecular studies on one of the cases showed a <i>KRAS</i> p.G12V mutation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The cytologic features of this distinctive, indolent neoplasm are important to recognize because patients with papillary renal neoplasm with reverse polarity may be excellent candidates for partial nephrectomy or even active surveillance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"133 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142217990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrieving new clues about a dog breed’s “insane” cancer risk 找回狗种 "疯狂 "患癌风险的新线索
IF 3.2 3区 医学
Cancer Cytopathology Pub Date : 2024-09-08 DOI: 10.1002/cncy.22899
Bryn Nelson PhD, William Faquin MD, PhD
{"title":"Retrieving new clues about a dog breed’s “insane” cancer risk","authors":"Bryn Nelson PhD,&nbsp;William Faquin MD, PhD","doi":"10.1002/cncy.22899","DOIUrl":"10.1002/cncy.22899","url":null,"abstract":"&lt;p&gt;Golden retrievers, consistently among the most popular dog breeds in the United States, are known as playful and family-friendly companions that are eager to please. A large longitudinal study, now in its 12th year, has revealed an additional, devastating trait: three of every four documented retriever deaths so far have been linked to cancer—by far the highest rate for any breed and among the highest rates of any animal. Of those cancer deaths, 70% are due to hemangiosarcoma, an aggressive blood vessel malignancy that is almost always fatal except for an uncommon cutaneous subtype.&lt;/p&gt;&lt;p&gt;If cuddlier than the unusually cancer-resistant rodents known as naked mole-rats, golden retrievers are at the opposite end of the susceptibility spectrum, making them another focal point of research. Teasing out cancer-associated factors, researchers say, could help to improve the beloved dogs’ longevity—as well as our own.&lt;/p&gt;&lt;p&gt;The Denver-based Morris Animal Foundation launched the biggest research effort to date, the Golden Retriever Lifetime Study, in 2012.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Veterinary researchers there enrolled 3044 privately owned dogs throughout the United States (all between 6 months and 2 years of age) to investigate not only the incidence but also environmental and genetic risk factors for cancers and other diseases, such as cognitive decline and osteoarthritis. With the oldest participants now turning 14 years old, Julia Labadie, DVM, PhD, MSPH, the study’s principal investigator, says that studying aging in dogs has emerged as an unanticipated additional goal.&lt;/p&gt;&lt;p&gt;“We have now a cohort of pretty old golden retrievers,” she says, noting that a significant fraction of those survivors could die of non-cancer causes. “So I think there’s a lot of questions that we can answer about the dogs that don’t get cancer and the dogs that live longer than the normal lifespan for golden retrievers that we always quote of about 10 to 12 years.”&lt;/p&gt;&lt;p&gt;Another recent study already is hinting that at least part of the longevity difference may be linked to variants in a gene encoding an epidermal growth factor receptor. Led by Robert Rebhun, DVM, PhD, chair of medical oncology at the University of California Davis School of Veterinary Medicine, the researchers discovered that a variant in a noncoding region of the &lt;i&gt;ERBB4&lt;/i&gt; gene (also known as &lt;i&gt;HER4&lt;/i&gt;) grants golden retrievers an extra 2 years of life on average.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Interestingly, &lt;i&gt;ERBB4&lt;/i&gt; appears to have a “good variant” that is associated with longer lifespans and a “bad variant” that is associated with shorter lifespans.&lt;/p&gt;&lt;p&gt;Because longevity in the breed is highly influenced by cancer, the genetic variants are almost certainly associated with cancer as well, says coauthor Michael Kent, DVM, MS, a professor of radiation oncology at the veterinary school. Other research has found that &lt;i&gt;ERBB4&lt;/i&gt; can serve as both a tumor suppressor and an oncogene.&lt;/p&gt;&lt;p&gt;“Everyone thoug","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 9","pages":"541-542"},"PeriodicalIF":3.2,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22899","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142165279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic performance of fine-needle aspiration in soft tissue tumors: Application of the World Health Organization System for Reporting Soft Tissue Cytopathology and risk of malignancy assessment 软组织肿瘤细针穿刺的诊断性能:世界卫生组织软组织细胞病理学报告系统的应用及恶性肿瘤风险评估。
IF 3.2 3区 医学
Cancer Cytopathology Pub Date : 2024-08-30 DOI: 10.1002/cncy.22897
Pawel Gajdzis MD, PhD, Hervé J. Brisse MD, PhD, Jerzy Klijanienko MD, PhD, MIAC
{"title":"Diagnostic performance of fine-needle aspiration in soft tissue tumors: Application of the World Health Organization System for Reporting Soft Tissue Cytopathology and risk of malignancy assessment","authors":"Pawel Gajdzis MD, PhD,&nbsp;Hervé J. Brisse MD, PhD,&nbsp;Jerzy Klijanienko MD, PhD, MIAC","doi":"10.1002/cncy.22897","DOIUrl":"10.1002/cncy.22897","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Recently, a new World Health Organization Reporting System for Soft Tissue Cytopathology (WHO System) was introduced. To analyze the value of this system, routine fine-needle aspiration soft tissue tumor (STT) cases were reviewed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Cytology samples of STTs collected between 1954 and 2022 at the Institut Curie were used (2214 cases, including 1376 primary tumors). All specimens were classified according to the predominant cytomorphological pattern and the WHO System. The diagnostic accuracy and risk of malignancy (ROM) in each category were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Final diagnoses revealed 1236 malignancies and 978 benign or low-risk tumors. The original cytological evaluation led to 21 false-negative results (0.85%) and 29 false-positive results (1.17%). Sensitivity, specificity, positive predictive value, and negative predictive value were 98.3%, 92.1%, 97.5%, and 94.2%, respectively. Overall diagnostic accuracy was 94.2%. The ROM calculated according to the WHO System was 29.87%, 2.49%, 39.62%, 51.43%, 68.42%, and 97.69% in the nondiagnostic, benign, atypical, soft tissue neoplasm of uncertain malignant potential, suspicious for malignancy, and malignant categories, respectively; however, it varied broadly depending on the morphological pattern (62.78% in spindle cell tumors, 84.58% in myxoid tumors, 3.00% in lipomatous tumors, 78.15% in epithelioid tumors, 94.26% in pleomorphic tumors, and 100% in round cell tumors).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Cytology of STTs is a powerful diagnostic method. Some cytological patterns overlap in different morphological groups, and the possibility of false-negative and false-positive diagnoses may persist. This analysis evidenced utility of the WHO System, especially when combined with morphological pattern assessment. Subclassification in particular diagnostic categories allowed for calculation of the ROM, which is crucial for optimal patient management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 12","pages":"768-778"},"PeriodicalIF":3.2,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative genomic and immunopathologic analysis of lung adenocarcinomas with and without cytology-proven malignant pleural effusions 对有和无细胞学证实的恶性胸腔积液的肺腺癌进行基因组和免疫病理学比较分析。
IF 3.2 3区 医学
Cancer Cytopathology Pub Date : 2024-08-29 DOI: 10.1002/cncy.22900
Cristiana M. Pineda MD, PhD, Adnan Majid MD, Daniel B. Costa MD, PhD, Paul A. VanderLaan MD, PhD
{"title":"Comparative genomic and immunopathologic analysis of lung adenocarcinomas with and without cytology-proven malignant pleural effusions","authors":"Cristiana M. Pineda MD, PhD,&nbsp;Adnan Majid MD,&nbsp;Daniel B. Costa MD, PhD,&nbsp;Paul A. VanderLaan MD, PhD","doi":"10.1002/cncy.22900","DOIUrl":"10.1002/cncy.22900","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lung cancer complicated by malignant pleural effusions (MPEs) is associated with significantly increased morbidity and mortality, yet the mechanisms of MPE development remain poorly understood. This study sought to elucidate whether there were specific genomic alterations and/or immunologic biomarkers associated with the presence of MPEs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Analysis of comprehensive genomic and immunologic profiling for 275 locally advanced (stage III) or advanced (stage IV) lung adenocarcinomas was subcategorized into cytology-confirmed MPE-positive (MPE+; <i>n</i> = 139 stage IV) and MPE-negative (MPE−; <i>n</i> = 30 stage III + <i>n</i> = 106 stage IV) groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Smoking frequency (<i>p</i> = .0001) and tumor mutational burden (<i>p</i> &lt; .001) were demonstrated to be lower in the MPE+ group compared to the MPE− group. Median overall survival in the MPE+ group was shorter than in the MPE− group across all data (2.0 vs. 5.5 years; <i>p</i> &lt; .0001) and for smokers (1.2 vs. 6.4 years; <i>p</i> &lt; .0001). There were a number of differences at the genomic level across all cases and when stratifying by smoking status, including a higher frequency of <i>EGFR</i> mutations and a lower frequency of <i>STK11</i> mutations in the MPE+ cohort. Finally, investigation of the comutational profiles of tumors by MPE status revealed differences in <i>TP53</i>- and <i>STK11</i>-mutant tumors between the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Overall, these findings imply that there are both clinical and genetic factors associated with advanced lung adenocarcinoma MPEs. Future studies of these alterations may prove important both for understanding the pathophysiology of MPE development in advanced cancer and for the earlier detection of at-risk patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 12","pages":"788-798"},"PeriodicalIF":3.2,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilization of an artificial intelligence–enhanced, web-based application to review bile duct brushing cytologic specimens: A pilot study 利用人工智能增强型网络应用程序审查胆管刷洗细胞学标本:试点研究。
IF 3.2 3区 医学
Cancer Cytopathology Pub Date : 2024-08-29 DOI: 10.1002/cncy.22898
Neil B. Marya MD, Patrick D. Powers, Melanie C. Bois MD, Christopher Hartley MD, Sarah E. Kerr MD, Judith Jebastin Thangaiah MBBS, MD, Daniel Norton BA, Barham K. Abu Dayyeh MD, MPH, Richard Cantley MD, Vinay Chandrasekhara MD, Gregory Gores MD, Ferga C. Gleeson MB, BCh, Ryan J. Law DO, Zahra Maleki MD, John A. Martin MD, Liron Pantanowitz MB, BCh, Bret Petersen MD, Andrew C. Storm MD, Michael J. Levy MD, Rondell P. Graham MBBS
{"title":"Utilization of an artificial intelligence–enhanced, web-based application to review bile duct brushing cytologic specimens: A pilot study","authors":"Neil B. Marya MD,&nbsp;Patrick D. Powers,&nbsp;Melanie C. Bois MD,&nbsp;Christopher Hartley MD,&nbsp;Sarah E. Kerr MD,&nbsp;Judith Jebastin Thangaiah MBBS, MD,&nbsp;Daniel Norton BA,&nbsp;Barham K. Abu Dayyeh MD, MPH,&nbsp;Richard Cantley MD,&nbsp;Vinay Chandrasekhara MD,&nbsp;Gregory Gores MD,&nbsp;Ferga C. Gleeson MB, BCh,&nbsp;Ryan J. Law DO,&nbsp;Zahra Maleki MD,&nbsp;John A. Martin MD,&nbsp;Liron Pantanowitz MB, BCh,&nbsp;Bret Petersen MD,&nbsp;Andrew C. Storm MD,&nbsp;Michael J. Levy MD,&nbsp;Rondell P. Graham MBBS","doi":"10.1002/cncy.22898","DOIUrl":"10.1002/cncy.22898","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The authors previously developed an artificial intelligence (AI) to assist cytologists in the evaluation of digital whole-slide images (WSIs) generated from bile duct brushing specimens. The aim of this trial was to assess the efficiency and accuracy of cytologists using a novel application with this AI tool.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Consecutive bile duct brushing WSIs from indeterminate strictures were obtained. A multidisciplinary panel reviewed all relevant information and provided a central interpretation for each WSI as being “positive,” “negative,” or “indeterminate.” The WSIs were then uploaded to the AI application. The AI scored each WSI as positive or negative for malignancy (i.e., computer-aided diagnosis [CADx]). For each WSI, the AI prioritized cytologic tiles by the likelihood that malignant material was present in the tile. Via the AI, blinded cytologists reviewed all WSIs and provided interpretations (i.e., computer-aided detection [CADe]). The diagnostic accuracies of the WSI evaluation via CADx, CADe, and the original clinical cytologic interpretation (official cytologic interpretation [OCI]) were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 84 WSIs, 15 were positive, 42 were negative, and 27 were indeterminate after central review. The WSIs generated on average 141,950 tiles each. Cytologists using the AI evaluated 10.5 tiles per WSI before making an interpretation. Additionally, cytologists required an average of 84.1 s of total WSI evaluation. WSI interpretation accuracies for CADx (0.754; 95% CI, 0.622–0.859), CADe (0.807; 95% CI, 0.750–0.856), and OCI (0.807; 95% CI, 0.671–0.900) were similar.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This trial demonstrates that an AI application allows cytologists to perform a triaged review of WSIs while maintaining accuracy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 12","pages":"779-787"},"PeriodicalIF":3.2,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AICyte-alone capabilities as an independent screener for triaging cervical cytology using a 50% negative cutoff value AICyte-alone 可作为一种独立的筛选器,使用 50% 阴性临界值对宫颈细胞学检查进行分流。
IF 3.2 3区 医学
Cancer Cytopathology Pub Date : 2024-08-19 DOI: 10.1002/cncy.22896
Xianxu Zeng MD, PhD, David Starr MD, Juan Li MD, Xuejie Bi MD, Chun Wang MD, Xinru Bai MD, Yanxue Yin MD, Xue Wu MD, Jingjing Wei MD, Hui Du MD, PhD, Wenkui Dai PhD, Changzhong Li MS, Xiangchen Wu PhD, Ruifang Wu MD, Chengquan Zhao MD
{"title":"AICyte-alone capabilities as an independent screener for triaging cervical cytology using a 50% negative cutoff value","authors":"Xianxu Zeng MD, PhD,&nbsp;David Starr MD,&nbsp;Juan Li MD,&nbsp;Xuejie Bi MD,&nbsp;Chun Wang MD,&nbsp;Xinru Bai MD,&nbsp;Yanxue Yin MD,&nbsp;Xue Wu MD,&nbsp;Jingjing Wei MD,&nbsp;Hui Du MD, PhD,&nbsp;Wenkui Dai PhD,&nbsp;Changzhong Li MS,&nbsp;Xiangchen Wu PhD,&nbsp;Ruifang Wu MD,&nbsp;Chengquan Zhao MD","doi":"10.1002/cncy.22896","DOIUrl":"10.1002/cncy.22896","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>AICyte has previously demonstrated a potential role in cervical cytology screening for reducing the workload by using a 50% negative cutoff value. The aim of the current study is to evaluate this hypothesis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors used the Ruiqian WSI-2400 (with the registered trademark AICyte) to evaluate a collection of 163,848 original cervical cytology cases from 2018 to 2023 that were collected from four different hospital systems in China. A breakdown of cases included 46,060 from Shenzhen, 67,472 from Zhengzhou, 25,667 from Shijiazhuang, and 24,649 from Jinan. These collected cases were evaluated using the AICyte system, and the data collected were statistically compared with the original interpretative results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In 98.80% of all artificial intelligence cases that were designated as not needing further review, the corresponding original diagnosis was also determined to be negative. For any cases that were designated atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion or higher, the sensitivity and negative predictive value were 90.77% and 98.80%, respectively. The sensitivity and negative predictive value were greater in cases designated as low-grade squamous intraepithelial lesion or higher at 98.92% and 99.94%, respectively. Of the 49 low-grade squamous intraepithelial lesion or higher that were designed by AICyte as not needing further review, the cytohistologic correlation revealed eight cases of cervical intraepithelial neoplasia 1 and 18 negative cases; and the remaining cases were without histologic follow-up. In practice, AICyte used at a 50% negative cutoff value could reduce the anticipated workload if a protocol were implemented to label cases that qualified within the negative cutoff value as not needing further review, thereby finalizing the case as negative for intraepithelial lesions and malignancy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>For pathologic practices that do not have cytotechnologists or in which the workflow is sought to be optimized, the artificial intelligence system AICyte alone to be an independent screening tool by using a 50% negative cutoff value, which is a potential assistive method for cervical cancer screening.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 11","pages":"723-730"},"PeriodicalIF":3.2,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22896","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信